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Abstract
The electronic health record (EHR) provides an unprecedented opportunity to build ac-
tionable tools to support physicians at the point of care. In this paper, we introduce deep
survival analysis, a hierarchical generative approach to survival analysis in the context of
the EHR. It departs from previous approaches in two main ways: (1) all observations,
including covariates, are modeled jointly conditioned on a rich latent structure; and (2)
the observations are aligned by their failure time, rather than by an arbitrary time zero
as in traditional survival analysis. Further, it handles heterogeneous data types that occur
in the EHR. We validate deep survival analysis by stratifying patients according to risk of
developing coronary heart disease (CHD) on 313,000 patients corresponding to 5.5 million
months of observations. When compared to the clinically validated Framingham CHD risk
score, deep survival analysis is superior in stratifying patients according to their risk.
1. Introduction
Our goal is to use electronic health record (EHR) data to estimate the time of a future
event of interest, namely, to carry out survival analysis in a healthcare context. Accurately
estimating the time to an event improves clinical decision support by allowing physicians
to take risk-calibrated actions. As a motivating example, consider coronary heart disease
(CHD). It is the leading cause of death worldwide (Hansson, 2005; Pagidipati and Gaziano,
2013). This condition, also known as coronary artery disease or ischemic heart disease, is
the most common type of heart disease and causes 1 in every 4 deaths. There are effec-
tive preventative therapies for CHD that can significantly reduce the risk of morbidity and
mortality: antiplatelet therapy (ISIS-2 Collaborative Group, 1988), statin therapy (Scandi-
navian Simvastatin Survival Study Group, 1994; Sacks et al., 1996; Shepherd et al., 1995),
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hypertensive therapy (Neal et al., 2000), and lifestyle interventions (Hjermann et al., 1981;
Schuler et al., 1992). Given the numerous effective strategies for primary prevention (no
prior CHD event) and secondary prevention (prior history of CHD event), there is great
value to identifying those individuals at high risk of experiencing a CHD event. This is
particularly important because these interventions, albeit effective, are not risk free.
The challenge of administering treatment based on risk pervades the clinical decision pro-
cess, and risk scores are in use for many conditions, such as prostate cancer (Thompson
et al., 2013), breast cancer (Gail et al., 1989), and stroke (Gage et al., 2001).
The standard approach to developing risk scores hinges on using a curated set of patient
data to regress covariates to the time of failure. The significant covariates in the analysis
are then summarized in a easy-to-use table (for CHD see Wilson et al. (1998)). However,
this approach has serious limitations with respect to EHR data. First, regression requires
complete measurement of the covariates for all patients; in practice, many are missing.
Second, the traditional approach requires all patients are aligned based on some initial event
(e.g., entry into trial, onset of a disease related to event of interest, start of medication,
etc.); EHR data does not enjoy a natural alignment. Third, the relationship between the
covariates and the time of the medical event is assumed to be linear, possibly with some
interaction terms; this limits the kind of relationships that may be found.
In this paper we propose a novel model for survival analysis from EHR data, which we
call deep survival analysis. Deep survival analysis handles the biases and other inherent
characteristics of EHR data, and enables accurate risk scores for an event of interest. The
key contributions of this work are:
• Deep survival analysis models covariates and survival time in a Bayesian framework.
This simplifies working with the missing covariates prevalent in the EHR.
• Deep exponential families (Ranganath et al., 2015b), a deep latent variable model,
forms the backbone of the generative process. This results in a non-linear latent
structure that captures complex dependencies between the covariates and the failure
time.
• Rather than enforcing an artificial time zero alignment for all patients, deep survival
analysis aligns all patients by their failure time (i.e., the event occurs or data is right
censored).
• Good preprocessing of EHR data allows deep survival analysis to include heteroge-
neous data types. In our study, we include vitals, laboratory measurements, medica-
tions, and diagnosis codes.
We studied a large dataset of 313,000 patient records and used deep survival analysis to
assess the risk of coronary heart disease. Deep survival analysis better stratifies patients
than the gold-standard, clinically validated CHD risk score (Wilson et al., 1998).
This paper is organized as follows. Section 2 reviews the fundamentals of traditional survival
analysis and motivates the need for better modeling tools for EHR data. Section 3.1 reviews
deep exponential families (Ranganath et al., 2015b) and Section 3.2 discusses our alignment
strategy for deep survival analysis. Section 3.3 describes the modeling assumptions behind
deep survival analysis; Section 4.2 gives details of our scalable variational inference algo-
rithm. Section 4 describes the clinical scenario of CHD, data, experimental setup, baseline,
and evaluation metrics. Finally, Sections 5 and 6 discuss our results and conclusions.
2. Survival Analysis
In this section, we provide background on the task of survival analysis. We review the
traditional approaches, along with several variants that are relevant to our work. We then
delve into two of the primary limitations of current survival analysis techniques, which
hinder their use in EHR data.
2.1 Traditional Survival Analysis
Survival analysis models the time to an event from a common start (Kaplan and Meier,
1958). Examples of survival data include time to delivery from conception and time to re-
tirement from birth. Survival observations consist of two varieties. The first are observations
for which the exact failure time is known. The second, called censored observations, are
observations for which the failure time is known to be greater than a particular time. Both
types are represented as (t, c), pairs of positive times and binary censoring status.
Survival modeling assumes the observations, both censored and uncensored, come from
an unknown distribution. The two traditional methods for estimating the survival distri-
bution are the Kaplan-Meier estimator (Kaplan and Meier, 1958) and Cox proportional
hazards (Cox, 1972). The Kaplan-Meier estimator forms a nonparametric estimator for the
survival function, one minus the cumulative distribution function. Intuitively, it breaks a
stick of length one at points proportional to the fraction of patients that survived until that
point. Cox proportional hazards generalizes this estimator to include covariates. Finally,
Bayesian variations of these methods place priors on the parameters (Hjort, 1990).
2.2 Limitations of Traditional Survival Analysis for EHR Data
There are three significant limitations to using traditional survival methods on EHR data.
First, EHR data is usually high-dimensional and very sparse (Hripcsak and Albers, 2013;
Pivovarov et al., 2014). This makes it difficult to use traditional conditional models, which
cannot easily handle missing covariates
Second, traditional methods require aligning all patients based on a synchronization event.
This event can be entry to a clinical trial, the date of an intervention, or the onset of a
condition. However, the EHR for a patient can begin at any point in their lifetime and
at any point in their disease progression. Thus careful definition of entry point into study
are required when experimenting with traditional survival techniques on EHR data (e.g.,
Hagar et al. (2014); Perotte et al. (2015)). In this work, we seek methods that are able
to evaluate risk at any point in time, not only points in time that correspond to such a
synchronization event.
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Figure 1: A comparison of traditional survival analysis (top frame) and failure aligned
survival analysis (bottom frame). A filled circle represents an observed event, while an
empty circle represents a censored one. In the case of standard survival analysis, patients
in a cohort are aligned by a starting event. In failure aligned survival analysis, patients are
aligned by a failure event.
Third, regression-based approaches to survival analysis often assume a linear function of the
covariates. Nonlinear interaction terms are sometimes introduced but must be limited (often
based on expert opinion) because of the combinatorial explosion of possibilities. Models with
greater flexibility can incorporate nonlinear relationships between combinations of covariates
and time-to-event.
3. Deep Survival Analysis
We introduce deep survival analysis, a hierarchical generative approach for survival analysis.
It departs from previous approaches in two primary ways. First, all observations, including
covariates, are modeled jointly and conditioned on a rich latent structure. Second, patient
records align by their failure time rather than by entry time, thus resolving the ambiguity
of entry to the EHR.
3.1 Deep Exponential Families
When not modeling the covariates, missing covariates are usually imputed using population-
level statistics. In contrast, we build a joint model for both the covariates and the survival
times, where the covariates and survival times are specified conditioned on a latent process.
This strategy requires a rich latent process; we use deep exponential families (Ranganath
et al., 2015b).
Deep exponential families (DEF) are a class of multi-layer probability models built from
exponential families (Brown, 1986). In deep exponential families, each observation has L
layers of latent variables. Each layer conditions on the previous layer of latent variables.
Formally, let n be the index of the data, expfam(·) be an exponential family distribution
with natural parameter, g(·;W ) denote a link function with parameters W with prior p(W ),
and η be a hyperparameter. The generative process for the latent variables is
zn,L,j ∼ expfamL(η)
zn,`,j ∼ expfam`(g`(zn,l+1,Wl,j)).
The observations for the ith data point are drawn conditional on the vector zi,1. We
shorthand the draw of the last layer, zn,1 as zn ∼ DEF(W). DEFs have been successful at
modeling text, recommender systems, and images. They handle missing data better than
competitive latent variable models and state-of-the-art density estimators (Rezende et al.,
2014; Ranganath et al., 2015b). Thus, they are a promising prior for the latent structure
to model survival in the EHR.
3.2 Alignment by Failure
Censored survival observations are pairs (ti, ci), where ti denotes the time of the ith ob-
servation, and ci marks whether failure or censoring occurs at that time. Traditionally,
the time ti is measured from a common start point for each observation, such as birth or
pregnancy. As we mentioned earlier, this type of alignment is inappropriate in the context
of the EHR because people enter the EHR in different ways relative to to their underly-
ing health. This limitation of survival analysis was acknowledged by McCullagh (2013),
but their solution has only been tested on a small dataset, and does not directly apply to
censored observations.
We consider an event-centric ordering, which measures time backwards from the event of
interest, rather than measuring time forward from an artificial start time. At the event
all patients share the defining characteristics of the event, thus patients are similar at time
zero under this alignment. We handle censored observations as interval observations.
For each time point, this alignment models the time to failure from that time point. This is
a positive number which decreases when approaching failure. Censored events differs. For
censored patients, their failure must happen (if it happens) after their last interaction with
the EHR; their time of interest is an interval greater than the time of their last visit to the
EHR. As such, event-centric ordering of data consists of pairs (ti, ci). See Figure 1 for a
graphical comparison of this versus the standard survival setup.
In this approach, every interaction with the EHR has a (possibly censored) time from even-
t/failure associated with it. This means the interactions can be modeled exchangeably,
which trades statistical efficiency of persisting patient information over time for compu-
tational efficiency. We take this approach. Each event of interest in the EHR represents
a different survival alignment frame. Thus, we can investigate several survival tasks by
choosing an event of interest and aligning by its timing. This contrasts traditional survival
analysis, which requires a careful decision about the start time.
To model the time from event, we use a Weibull distribution, a popular distribution in
survival analysis. Let λ be the scale and k be the shape, the Weibull distribution is
p(t) = k/λ (t/λ)k−1 e−(
t
λ)
k
.
It has support over the positive reals and its parameters are constrained to be positive.
Its expectation is λΓ(1 + 1k ). The parameter k control how the density looks. When
k < 1 most of the mass is concentrated near zero; when k = 1 this distributions matches
the exponential; when k > 1, the distribution places mass around its expectation. For a
censored observation, The likelihood is the amount of probability the model places after
censoring, i.e., one minus the cumulative distribution function. For the Weibull, this is
exp(− ( tλ)k), which gets large as the scale grows.
3.3 Generative Process for Deep Survival Analysis
Let x denote the set of covariates, β be the parameters for the data with some prior p(β),
k be a fixed scalar, and let n index an observation. The generative model for deep survival
analysis is
b ∼ Normal(0, σb)
a ∼ Normal(0, σW )
zn ∼ DEF(W)
xn ∼ p(· |β, zn)
tn ∼Weibull(log(1 + exp(z>n a+ b), k). (1)
The latent variable zi comes from a DEF which then generates the observed covariates and
the time to failure. The function log(1 + exp(·)), called the softplus, maps from the reals to
the positives to output a valid scale for the Weibull. Given covariates x, the model makes
predictions via the posterior predictive distribution:
p(t |x) =
∫
z
p(t | z)p(z |x)dz.
The complexity of the predictions depends on the complexity of the distribution z. Note
this predictive distribution exists and is consistent even if data are missing.
For electronic health records the x contain several data types. We consider laboratory test
values (labs), medications (meds), diagnosis codes, and vitals. We assume each of these
data types are generated independently, conditional on the latent structure
p(xn |β, zn) = p(xlabsn | zn, βlabs)p(xmedsn | zn, βmeds)p(xdiagnosesn | zn, βdiagnoses)p(xvitalsn | zn, βvitals).
We emphasizes that they are marginally dependent.
The data types in the EHR can be grouped by whether they are real valued (labs and vitals)
or counts (diagnoses and medications). Next we define the likelihood for each group.
Real-Valued Observations. Real-valued observations in EHR are heavy tailed and are
prone to data entry errors (Hauskrecht et al., 2013). This leads to extreme outliers that
may badly corrupt estimates of non-robust models such as those based on the Gaussian.
We model the real-valued data with the Student-t distribution, a continuous mixture of
Gaussians across scales, which is more robust to outliers. Given parameters, βlabsWi , β
labs
bi
and
degrees of freedom ν, the conditional density of the ith lab, is
p(xlabsn,i |βlabsWi , βlabsbi , zn) =
Γ(ν+12 )√
νpi
(
1 +
(xlabsn,i − (z>n βlabsWi + βlabsbi )2
ν
)− ν+1
2
.
This is a Student-t distribution whose mode is at z>n βlabsWi +β
labs
bi
a function of both the data
point specific latent variables and the parameters shared across data points. The degrees of
freedom controls to which extent the distribution resembles a Naussian, where large values
look more Gaussian. We place Gaussian priors on both Wi and bi. The likelihood follows
similarly for the vitals.
Count Valued Observations. Unlike the laboratory tests and the vitals, the count-
valued observations are highly dimensional and sparse. To handle counts robustly, we
model them as binary values, one if the count is non-zero and zero otherwise. We model
the ith medication with parameters βmedsWi as
p(xmedsn,i |βmedsWi , zn) ∼ Bernoulli(1− exp(z>n βmedsWi ))),
where βmedsWi has a log-Gaussian prior. This likelihood has the added benefit that the total
likelihood and its gradient can be computed in time proportional to the number of nonzero
elements (Ranganath et al., 2015a). We overdisperse the Bernoulli likelihood by the number
of medications to balance this component with the time from failure. The diagnoses are
modeled in the same manner.
4. Experimental Setup
We apply deep survival analysis to data from a large metropolitan hospital. We use the
fitted model to predict coronary heart disease risk (CHD). Access to data and experiments
was approved after review by the Columbia University Institutional Review Board.
4.1 Dataset
Our dataset comprises the longitudinal records of 313,000 patients from the Columbia Uni-
versity Medical Center clinical data warehouse. The patient population included all adults
(>18 years old) that have at least 5 months (not necessarily consecutive) where at least one
observation was recorded.
The patient records contain documentation resulting from all settings, including inpatient,
outpatient, and emergency department visits. Observations included 9 vital signs, 79 labo-
ratory test measurements, 5,262 medication orders, and 13,153 diagnosis codes.
Data Preprocessing. All real-valued measurements and discrete variables were aggre-
gated at the month level, leading to binned observations for each patient and for each
month the patient had any recorded observation. The expected value over the course of
each month was computed for continuous measurements such as vitals and laboratory mea-
surements and the presence of discrete elements such as medication orders and diagnosis
codes was encoded as a binary variable.
4.2 Baseline and Model Setup
Baseline. The Framingham CHD risk score was developed in 1998 and is one of the
earliest validated clinical risk scores. It is a gender-stratified algorithm for estimating the
10-year coronary heart disease risk of an individual. Aside from gender, this score takes
into consideration age, sex, LDL cholesterol, HDL cholesterol, blood pressure, diabetes, and
smoking. For example, a 43-year-old (1 point) male patient with an LDL level of 170 mg/dl
(1 point), an HDL level of 43 mg/dl (1 point), a blood pressure of 140/90 (2 points), and
no history of diabetes (0 points) or smoking (0 points) would have a risk score of 5 which
would correspond to a 10 year CHD risk of 9% (Wilson et al., 1998).
The score was validated using curated data from the Framingham Heart Study. It was
shown to have good predictive power of 10-year risk with a concordance of 0.73 for men
and 0.77 for women. However, this score has lower performance when applied to EHR
data (Pike et al., 2016).
Model Setup and Hyperparameters. We set the shape of the Weibull to be 2. The
exponential family used inside the DEF is a Gaussian. The mean and inverse softplus
variance functions for each layer are a 2 layer perceptron with rectified linear activations.
We set Normal priors to have mean zero and variance one.
We let all methods run for 6,000 iterations and assess convergence on a validation set. On a
40-core Xeon Server with 384 GB of RAM, 6,000 iterations for all patients in the training set
completed in 7.5 hours. Due to the high variance in patient record lengths, we subsample
observations during inference inversely to the length of the patient records.
Inference. We approximate the posterior distribution with variational inference (Jordan
et al., 1999) for the observation specific latent variables in the DEF and do maximum-
a-posteriori inference on the parameters. We choose the approximating family to be the
mean-field family where each latent variables gets its own independent parameterization.
We use black box variational methods (Ranganath et al., 2014) with reparameterization
gradients (Kingma and Welling, 2014; Rezende et al., 2014) to approximate the posterior
without needing model specific computation. To scale to the large data, we subsample
data batches (Hoffman et al., 2013) of size 240 and parallelize computation across data in
a batch. We use RMSProp with scale 0.0001 and Nesterov momentum of 0.9 as learning
rates during optimization.
4.3 Evaluation
Of the 313,000 patients in the study, 263,000 were randomly selected for training, 25,000 for
validation, and 25,000 for testing. We assessed convergence with the validation cohort and
evaluated concordance on the test cohort. A CHD event was defined as the documentation of
any ICD-9 diagnosis code with the following prefixes: 413 (angina pectoris), 410 (myocardial
infarction), or 411 (coronary insufficiency). In our experiments, we vary the dimensionality
of zn to assume the values of K ∈ {5, 10, 25, 75, 100}. The layer size for the perceptrons were
set to equal the dimensionality of zn in each experiment. We evaluate both the baseline
risk score and deep survival analysis with the concordance (Harrell et al., 1982).
While concordance enables the comparison of deep survival analysis to the baseline, it only
roughly captures the accuracy of the temporal prediction of the models. In deep survival
analysis, we can compute the predictive likelihood of the held-out set according to the model,
which enables us to capture how well the model predicts failure in time. For internal model
validation, we thus rely on predictive likelihood. Predictive likelihood is evaluated as the
expected log probability of the observed time until failure conditioned on the observed
covariates for a given patient in a given month.
5. Results
Missing data is a core challenge of electronic health record data analysis and temporal
analysis. We first report the extent of incomplete observations in our dataset. We then
report results for the baseline CHD risk model and deep survival analysis. We also report
internal validation of deep survival analysis which include only a single data type.
5.1 Missing observations in EHR data
For estimating CHD risk in 10 years, the widely used guideline-based CHD risk score calcu-
lators used routinely by clinicians require input of seven variables: age, sex, current smoking
status, total cholesterol level, HDL cholesterol level, systolic blood pressure, and whether
patient takes blood pressure medication. We examined how many patients had at least one
month in their record, where the most basic, critical set of variables were observed (LDL
level, HDL level, and blood pressure). In the full dataset, only 11.8% of patients have a
complete month, and 1.4% of months are complete.
5.2 Model Performance and Predictive Likelihood
The baseline CHD risk score yielded 65.57% in concordance over the held out test set.
Table 1 shows the concordance of the deep survival analysis for different values of K. When
considering the full deep survival with all data types considered, the best performance was
obtained for K=50.
Model Concordance (%)
Baseline Framingham Risk Score 65.57
Deep Survival Analysis; K=10 69.35
Deep Survival Analysis; K=5 70.45
Deep Survival Analysis; K=25 71.20
Deep Survival Analysis; K=75 71.65
Deep Survival Analysis; K=100 72.71
Deep Survival Analysis; K=50 73.11
Table 1: Concordance on a held-out set of 25,000 patients for different values of K and for
the baseline risk score. All deep survival analysis dimensionalities outperform the baseline.
When examining the deep survival analysis with the best concordance on the held out set
(K=50), we then asked how well each individual data type predicts failure. The following
four models were thus trained: deep survival analysis including vitals only, diagnosis codes
only, laboratory tests only, and medications only. All models included age and gender.
Their individual predictive likelihood was computed on the same month bins, even in the
absence of observations of a specific data type. The diagnosis-only model yielded the best
predictive likelihood.
Data Type Likelihood
Medications Only -1.24899
Laboratory Tests Only -0.998774
Vitals Only -0.961827
Diagnoses Only -0.855385
Table 2: Predictive likelihood of deep survival analysis (K=50) for individual data types.
The diagnoses perform best.
6. Discussion
In this paper we introduce a new method for survival analysis built to handle the inherent
characteristics of EHR data. While traditional survival analysis requires carefully curated
research datasets, our approach easily handles the sparsity and heterogeneity of EHR ob-
servations. We estimate deep survival analysis on the entire data from a large metropolitan
hospital in a matter of hours. When compared to one of the state-of-the-art, clinically vali-
dated risk score in the context of coronary heart disease, deep survival analysis yields a more
accurate stratification of patients. Our approach holds particular promise for developing
risk scores from observational data for conditions where there is no known risk score.
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